ONKOLOGIE / Onkologie. 2023;17(2):108-112 / www.onkologiecs.cz 112 PŘEHLEDOVÉ ČLÁNKY Vliv cílené léčby BRAF a MEK inhibitory na imunitní systém u metastazujícího melanomu 9. Long GV, Lebbe C, Atkinson V, et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. J Clin Oncol. 2019;37(15_suppl):9531-9531. 10. Nathan P, Dummer R, Long GV, et al. Melanoma and other skin tumors LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. 2020 [cited 2020 Nov 1]. Available from: https:// doi.org/10.1016/j.annonc.2020.08.2273. 11. Ho PC, Meeth KM, Tsui YC, et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res. 2014;74(12):3205-3217. doi: 10.1158/00085472.CAN-13-3461. Epub 2014 Apr 15. PMID: 24736544; PMCID: PMC4063281. 12. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152-172. doi: 10.1111/j.1600-065X.2009.00782.x. PMID: 19426221; PMCID: PMC3826168. 13. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559-563. doi: 10.1038/nature13490. Epub 2014 Jul 13. PMID: 25043024; PMCID: PMC4301845. 14. Bradley SD, Chen Z, Melendez B, et al. BRAFV600E Co- -opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3(6):602-609. doi: 10.1158/2326-6066.CIR-15-0030. Epub 2015 Mar 20. PMID: 25795007; PMCID: PMC4457616. 15. Koya RC, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res [Internet]. 2012 Aug 15 [cited 2023 Mar 19];72(16):3928-3937. Available from: https://pubmed. ncbi.nlm.nih.gov/22693252/. 16. Allegrezza MJ, Rutkowski MR, Stephen TL, et al. IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Res [Internet]. 2016 May 1 [cited 2023 Mar 19];76(9):2561-2572. Available from: https://pubmed.ncbi. nlm.nih.gov/26980764/. 17. Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639-51. doi: 10.1158/1078-0432.CCR-14-2339. Epub 2015 Jan 14. PMID: 25589619. 18. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691. PMID: 25787767; PMCID: PMC4765379. 19. Hugo W, Shi H, Sun L, et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell [Internet]. 2015 Sep 10 [cited 2020 Feb 29];162(6):1271-1285. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26359985. 20. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med [Internet]. 2015 Mar 18 [cited 2023 Mar 19];7(279). Available from: https:// pubmed.ncbi.nlm.nih.gov/25787767/. 21. Hong DS, Vence L, Falchook G, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012;18(8):2326-2335. doi: 10.1158/1078-0432. CCR-11-2515. Epub 2012 Feb 21. Erratum in: Clin Cancer Res. 2012 Jul 1;18(13):3715. PMID: 22355009. 22. Callahan MK, Masters G, Pratilas CA, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014;2(1):70-79. doi: 10.1158/2326-6066.CIR-13-0160. PMID: 24416731; PMCID: PMC3883307. 23. Ebert PJR, Cheung J, Yang Y, et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity [Internet]. 2016 Mar 15 [cited 2020 Feb 29];44(3):609-621. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/26944201. 24. Russo I, Miotto S, Saponeri A, et al. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opin Biol Ther [Internet]. 2020 Feb 6 [cited 2020 Feb 9];14712598.2020.1727440. Available from: https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1727440. 25. Steinberg SM, Zhang P, Malik BT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res [Internet]. 2014 Nov 1 [cited 2020 Feb 29];2(11):1044-1050. Available from: http://www.ncbi.nlm. nih.gov/pubmed/25183499. 26. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-1231. 27. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res [Internet]. 2012 Mar 1 [cited 2020 Feb 29];18(5):1386-1394. Available from: http://www. ncbi.nlm.nih.gov/pubmed/22156613. 28. Wilmott JS, Haydu LE, Menzies AM, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol [Internet]. 2014 Mar 1 [cited 2020 Feb 29];192(5):2505-2513. Available from: http://www.ncbi.nlm. nih.gov/pubmed/24489105. 29. Cooper ZA, Reuben A, Spencer CN, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016;5(3). 30. Pieper N, Zaremba A, Leonardelli S, et al. Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. Oncoimmunology [Internet]. 2018 Aug 3 [cited 2020 Feb 29];7(8):e1450127. Available from: http://www.ncbi.nlm. nih.gov/pubmed/30221038. 31. Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19(3):598-609. 32. Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res [Internet]. 2015 Apr 1 [cited 2023 Mar 19];21(7):1639-1651. Available from: https://pubmed.ncbi.nlm.nih.gov/25589619/. Řešením je ELEKTRONICKÉ PŘEDPLATNÉ Chcete číst aktuální články časopisu ONKOLOGIEON-LINE? ◼ www.onkologiecs.cz ČTĚTE IHNEDv podobě listovačky či ve formátu PDF ◼ bez přihlášení/předplatného jsou články přístupné až po 1 roce ◼ 5 čísel/rok – 660 Kč (vč. tematických příloh) Objednávejte v našem e-shopu➜ www.solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=